Latest Ionis News & Updates

See the latest news and media coverage for Ionis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Ionis

RNA- and DNA-targeted medicines developer

ionis.com

Headquarters: Carlsbad, United States
Founded year: 1989
Company type: Public company
Number of employees: 1,000–1,600
Industry: Pharmaceuticals

Last updated October 23

Latest news about Ionis

In short: Ionis secured FDA approvals for TRYNGOLZA and Zanvastro but faced cardio trial setbacks in 2026.

Company announcements

October 23 Ionis

Ionis partner Roche shows Phase 3 data for sefaxersen in IgAN

Sifaxersen reduced proteinuria by 43.1% relative to placebo at 37 weeks. The investigational therapy inhibits complement factor B and is well tolerated in the IMAgINATION study.

October 21 Ionis

Ionis partner GSK announces FDA approval for Hibsago in the US

Bepirovirsen treats chronic hepatitis B with unprecedented functional cure rates. Ionis licensed the drug to GSK and earns milestone payments and royalties.

October 16 Ionis

Ionis receives CHMP positive opinion for TRYNGOLZA in EU

The EMA committee recommends approval for treating severe hypertriglyceridemia. Final EC decision is expected in Q4 2026.

September 23 Ionis

Ionis reports positive Phase 3 sefaxersen data for IgA nephropathy,

Partner Roche's IMAgINATION study met primary endpoints. Interim results show significant proteinuria reduction with a favorable safety profile.

Media coverage

October 16 BioPharma Dive

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Hibsago is viewed as a potential "functional cure" for chronic infections and an important part of the British drugmaker's goal of reaching £40 billion in...

October 15 MarketWatch

Ionis Pharmaceuticals Gets CHMP Backing for Tryngolza in Severe Hypertriglyceridemia.

Ionis on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers Tryngolza as an adjunct to diet...

September 22 BioSpace

Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod

A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which ...

September 21 Reuters

Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients ‌with a rare inherited...

Never miss news about Ionis

Track Ionis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Ionis competitors & trending companies

Browse news for competitors to Ionis and other trending companies.